






**INFORMATION REGARDING PROPOSED BOARD OF DIRECTORS**

<p><b>Thomas von Koch</b></p> 	<p>Proposed for re-election as Director and proposed as new Chairman of the Board.</p>
<p>Year of birth</p>	<p>1966</p>
<p>Education/Experience</p>	<p>BSc Business and Economics, Stockholm School of Economics.</p> <p>CEO and Managing Partner at EQT Partners from 1 March 2014 – 31 December 2018.</p>
<p>Position in the Company</p>	<p>Director of the Board.</p> <p>Co-founder of Bactiguard and Chairman of the Board of Directors 2005-2013.</p>
<p>Other significant positions</p>	<p>Chairman of the Board of EQT Asia Pacific.</p> <p>Member of the Board of SWIB Holding AB (holding company for Smartwise Sweden AB and Procella Therapeutics AB).</p>
<p>Holdings of securities in the company</p>	<p>Class A shares: 2 000 000 (through legal entity).</p> <p>Class B shares: 4 125 878 (through legal entity and personal holdings).</p>
<p>Independence</p>	<p>Independent in relation to the Company and management. Not independent in relation to the Company's major shareholders.</p>
<p>Year elected to the Board of Directors</p>	<p>2019</p>

<p><b>Christian Kinch</b></p> 	<p>Proposed for re-election as Director and proposed as new deputy Chairman of the Board.</p>
<p>Year of birth</p>	<p>1966</p>
<p>Education/Experience</p>	<p>Studies at the Stockholm School of Economics.</p> <p>Founder and CEO at Kinchard AB and Netpharma AB.</p>
<p>Positions in the company</p>	<p>Director of the Board.</p> <p>CEO June 2015 – February 2020 and during 2005 – March 2014.</p> <p>Chairman of the Board of Directors March 2014 – June 2015 and from 2020.</p>
<p>Other significant positions</p>	<p>Board member of Swecare AB.</p> <p>Chairman of the Board of Directors of SWIB Holding AB (holding company for Smartwise Sweden AB and Procella Therapeutics AB).</p>
<p>Holdings of securities in the company</p>	<p>Class A shares: 2 000 000 (through legal entity).</p> <p>Class B shares: 4 125 977 (through legal entity and family).</p>
<p>Independence</p>	<p>Not independent in relation to the Company, the management or the Company's major shareholders.</p>
<p>Year elected to the Board of Directors</p>	<p>2005</p>

<p><b>Jan Ståhlberg</b></p> 	<p>Proposed for re-election as Director of the Board.</p>
<p>Year of birth</p>	<p>1962</p>
<p>Education/Experience</p>	<p>BSc Business and Economics, Stockholm School of Economics. Studies at the MBA program at New York University, Stern School of Business. Deputy CEO and deputy Chairman at EQT.</p>
<p>Positions in the company</p>	<p>-</p>
<p>Other significant positions</p>	<p>Founder and CEO of Trill Impact AB. Board member of ITB-Med AB. Board member of Trelleborg AB.</p>
<p>Holdings of securities in the company</p>	<p>Class B shares: 3 354 387 shares (personal holdings).</p>
<p>Independence</p>	<p>Independent in relation to the Company, management and the Company's major shareholders.</p>
<p>Year elected to the Board of Directors</p>	<p>2018</p>

<p><b>Anna Martling</b></p> 	<p>Proposed for re-election as Director of the Board</p>
<p>Year of birth</p>	<p>1969</p>
<p>Education/Experience</p>	<p>M.D, Karolinska Institutet.  Board Certified Surgeon  Ph.D, Karolinska Institutet  Docent, Karolinska Institutet  Professor of Surgery, Karolinska Institutet.</p> <p>Dean Campus North, Karolinska Institutet  Senior Consultant Surgeon, theme Cancer, Karolinska University Hospital  Research Group Leader, Karolinska Institutet.</p> <p>Member of the Board of Research at Karolinska Institutet (2015-2018).  Member of Board of Research KI/SLL (2015-2018).  Member of Faculty Board, Karolinska Institutet (2019- ).  Member of KI/Stockholm Region's management group (2019- ).</p>
<p>Positions in the company</p>	<p>-</p>
<p>Other significant positions</p>	<p>Previous and current missions as Board member of KI Cancer, StratCan and CIMED (all within Karolinska Institutet), St Erik's Eye hospital.</p>
<p>Holdings of securities in the company</p>	<p>Class B shares: 3 423 shares (personal holdings).</p>
<p>Independence</p>	<p>Independent in relation to the Company, management and the Company's major shareholders.</p>
<p>Year elected to the Board of Directors</p>	<p>2019</p>

<p><b>Cecilia Edström</b></p> 	<p>Proposed for re-election as Director of the Board</p>
<p>Year of birth</p>	<p>1966</p>
<p>Education/Experience</p>	<p>BSc Business and Economics, Stockholm School of Economics.</p> <p>Various positions within SEB and in the Group Management of Scania AB and TeliaSonera AB.</p>
<p>Position in the company</p>	<p>Recruited to Bactiguard prior to the IPO in 2014 and has held several leading roles in the Company.</p> <p>Chief Financial Officer (CFO) with responsibility for business development September 2017-February 2020.</p> <p>From June 2019 Executive Vice President.</p> <p>From February 5, 2020, CEO of the Company.</p>
<p>Other significant positions</p>	
<p>Holdings of securities in the company</p>	<p>Class B shares: 243 264 (personal holding)</p>
<p>Independence</p>	<p>Not independent in relation to the Company and management. Independent to the Company's major shareholders.</p>
<p>Year elected to the Board of Directors</p>	<p>2020</p>

